Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683631 · ClinicalTrials.gov registry record
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
A clinical trial, sponsored by University of Louisville.
- Completed
- Registry status
- 183
- Enrollment target
NCT00683631: Completed study, sponsored by University of Louisville.
NCT00683631 is a clinical trial that has completed, run by University of Louisville. The registered enrollment target is 183 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683631 has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- 183 participants
- Enrollment target
Study Summary
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
Interventions
- OTHER TheraSphere HUD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2004-01 |
| Est. Completion | 2021-04-01 |
What the finished NCT00683631 record still lists
NCT00683631 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere HUD is the first listed.
NCT00683631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00683631 about?
NCT00683631 is a clinical study titled "TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)". The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
What is the current status of trial NCT00683631?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2004-01. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT00683631?
The interventions under investigation include: TheraSphere HUD (OTHER).
Who is sponsoring clinical trial NCT00683631?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia